We will be contrasting the differences between CRISPR Therapeutics AG (NASDAQ:CRSP) and BioNTech SE (NASDAQ:BNTX) as far as dividends, analyst recommendations, profitability, risk, institutional ownership, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
CRISPR Therapeutics AG 60 0.00 34.37M -0.46 0.00
BioNTech SE 21 0.00 62.16M -0.57 0.00

Table 1 demonstrates CRISPR Therapeutics AG and BioNTech SE’s top-line revenue, earnings per share (EPS) and valuation.

Profitability

Table 2 provides us CRISPR Therapeutics AG and BioNTech SE’s net margins, return on assets and return on equity.

Net Margins Return on Equity Return on Assets
CRISPR Therapeutics AG 57,235,636.97% -2.6% -2%
BioNTech SE 294,039,735.10% 0% 0%

Liquidity

CRISPR Therapeutics AG has a Current Ratio of 8.3 and a Quick Ratio of 8.3. Competitively, BioNTech SE’s Current Ratio is 3.7 and has 3.7 Quick Ratio. CRISPR Therapeutics AG’s better ability to pay short and long-term obligations than BioNTech SE.

Analyst Recommendations

In next table is shown CRISPR Therapeutics AG and BioNTech SE’s ratings and recommendations.

Sell Ratings Hold Ratings Buy Ratings Rating Score
CRISPR Therapeutics AG 0 0 3 3.00
BioNTech SE 0 0 6 3.00

CRISPR Therapeutics AG’s upside potential is 8.55% at a $72 consensus target price. Competitively BioNTech SE has an average target price of $22.17, with potential downside of -36.66%. Based on the data shown earlier, CRISPR Therapeutics AG is looking more favorable than BioNTech SE, analysts opinion.

Institutional & Insider Ownership

Institutional investors owned 46.8% of CRISPR Therapeutics AG shares and 0% of BioNTech SE shares. Insiders owned roughly 0.4% of CRISPR Therapeutics AG’s shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
CRISPR Therapeutics AG 1% 49.37% 59.3% 63.07% 101.48% 153.31%
BioNTech SE 10.87% 40.22% 0% 0% 0% 71.14%

For the past year CRISPR Therapeutics AG has stronger performance than BioNTech SE

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its proprietary clustered, regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9)gene-editing platform in Switzerland. The CRISPR/Cas9 technology allows for changes to genomic DNA. It has a collaboration agreement with Vertex Pharmaceuticals, Incorporated to develop, manufacture, commercialize, sell, and use therapeutics; a license agreement with Anagenesis Biotechnologies SAS; and a service agreement with MaSTherCell SA to develop and manufacture allogeneic CAR-T therapies. The company also has research collaboration agreements with Neon Therapeutics and Massachusetts General Hospital Cancer Center to develop novel T cell therapies for cancer. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.




Source link